Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

DMBT1 in Adipose-Derived Stem Cell-Derived Exosomes Participates in Alleviating Ferroptosis to Promote Diabetic Wound Healing.

Liu Y., Wang J., Cai Y., Zhu X., Yuan Z., Dai J.

Animal Study on Diabetic Foot, Chronic Wound, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Rev Rep (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42530836
DOI
10.1007/s12015-026-11201-w

Abstract (original English)

Diabetic wounds represent one of the most severe complications of diabetes, and their clinical management remains challenging. This study investigated the therapeutic potential of adipose-derived stem cell-derived exosomes (ADSCs-Exo) for diabetic wounds. We isolated ADSCs and their exosomes, and by using Transwell and CCK-8 assays, we found that ADSCs-Exo were associated with proliferation and migration of keratinocytes and fibroblasts, and that they also enhanced the angiogenic activity of endothelial cells in vitro. In contrast, these promotive effects were significantly attenuated when exosomes derived from ADSCs with DMBT1 knockdown via siRNA (ADSCs siDMBT1 -Exo) were applied. In a diabetic mouse model, ADSCs-Exo treatment significantly accelerated wound healing, whereas the pro-healing capacity of ADSCs siDMBT1 -Exo was markedly reduced. To further explore the underlying mechanism, we performed RNA sequencing, which suggested that ADSCs-Exo might exert their therapeutic effects by alleviating ferroptosis and promoting cell proliferation. Subsequent experiments, including TEM, ROS assays, JC-1 staining, and tissue immunofluorescence, provided further support for these mechanistic findings. In summary, this study demonstrates that DMBT1 in ADSCs-Exo participates in alleviating ferroptosis in diabetic wound tissue, which may contribute to creating a favorable microenvironmen

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research